National Water Quality Month 2026: FDA vs. EPA Standards

Written by: Scott Steveson, Specialist, Wellness Quality Institute

Key Takeaways

• FDA bottled-water standards must match EPA tap-water standards in strictness, but testing frequency, public disclosure, and treatment rules differ in practice.
• Bottled water producers test coliform weekly and chemicals annually with no mandatory public reporting, while large tap-water systems test far more often and must issue annual Consumer Confidence Reports.
• Neither FDA nor EPA rules currently set standards or require disclosure for plastic or microplastic content in water.
• PFAS limits finalized by the EPA in 2024 will apply to bottled water by late 2028 if the FDA does not adopt matching standards first.
• Brands with laboratory data on plastic content can turn that evidence into a supported claim through the Wellness Quality Institute’s independent Plastic-Free Pathway Verification program at The Wellness Quality Institute.

How Tap and Bottled Water Standards Compare

Federal law requires FDA bottled-water standards and EPA tap-water standards to be equivalent at the minimum level, but they differ in practice. The two systems regulate many of the same contaminants, yet they use different testing schedules, reporting rules, and enforcement tools.

Under Section 410 of the FD&C Act, every time the EPA sets a new drinking-water standard, the FDA must adopt a matching bottled-water standard or publish a written explanation for why one is not needed within 180 days. That standard must be “no less stringent” than the EPA’s. If the FDA misses the deadline, the EPA’s rule automatically becomes the bottled-water standard.

PFAS, or per- and polyfluoroalkyl substances, currently test that linkage. PFAS are synthetic “forever chemicals” used in many products, and they do not break down easily in the environment. The EPA finalized a National Primary Drinking Water Regulation for six PFAS compounds in April 2024, setting limits ranging from 4 to 10 parts per trillion. The FDA has stated it is reviewing those limits and working toward corresponding bottled-water standards under 21 CFR 165.110, with the late-2028 automatic-adoption deadline described above.

A separate development affects public water systems. In May 2026, the EPA proposed allowing public water systems to request a two-year compliance extension. That proposal would move the PFOA and PFOS Maximum Contaminant Level (MCL, the legal ceiling for a substance in drinking water) deadline from April 2029 to April 2031, while keeping the MCLs themselves unchanged. Monitoring and reporting requirements remain in force regardless of whether a system receives an exemption.

Lead standards show another difference. The FDA caps lead in bottled water at 5 parts per billion (ppb). The EPA’s tap-water action level remains 15 ppb, with a separate 10 ppb trigger level under the Revised Lead and Copper Rule. The statutory “no less stringent” floor does not guarantee that the two systems always use the same numeric limit.

What FDA Labeling Rules Require for Bottled Water

Bottled water is regulated as a packaged food under 21 CFR Part 129, which covers how water is processed and bottled, and 21 CFR Part 165, which sets quality standards. Part 165 includes numeric limits for microbiological, physical, chemical, and radiological contaminants, covering more than 70 chemical substances. Producers must keep source-approval records along with all sampling and testing records and must show them during FDA inspections.

Federal rules do not require bottled water producers to publish those records or issue any equivalent of a Consumer Confidence Report (CCR). A CCR is the annual water-quality disclosure that every community tap-water system must send to customers. Some bottlers issue voluntary quality reports, but these reports are not standardized or federally required.

The EPA’s CCR rule, codified at 40 CFR Part 141, Subpart O, requires every community water system to deliver a CCR by July 1 each year. A community water system means any public water system with at least 15 year-round service connections or that regularly serves at least 25 year-round residents. The report must cover data collected during or prior to the previous calendar year. Starting with reports covering calendar year 2026 data (due July 1, 2027), systems serving 10,000 or more people must deliver CCRs twice annually under the 2024 Revised CCR Rule.

National Water Quality Month 2026: Why This Comparison Matters Now

National Water Quality Month in August highlights the safety of the water Americans drink, whether from a tap or a bottle. In 2026, this observance arrives during a period of active regulatory change. PFAS compliance timelines are under review, CCR reporting requirements are expanding, and the FDA is working toward its first bottled-water PFAS standards.

This moment creates a clear opportunity to look closely at what each framework requires and where both fall short. The three most consequential differences between FDA bottled-water rules and EPA tap-water rules are testing frequency, public disclosure, and treatment mandates. Each appears in the table below.

Regulatory Dimension	FDA — Bottled Water (21 CFR Part 129)	EPA — Tap Water (40 CFR Part 141)
Coliform (bacteria) testing frequency	Under 21 CFR 129.80, FDA requires total coliform testing at least once per week for finished bottled drinking water product, and non-public source water testing is required under 21 CFR 129.35.	Large systems serving more than 100,000 people must test 100 or more times per month under the Revised Total Coliform Rule (40 CFR Part 141).
Chemical contaminant testing frequency	At least once per year on a representative sample, and radiological contaminants at least once every four years under 21 CFR 129.35.	Frequency varies by contaminant and system size. PFAS initial monitoring requires two to four samples per 12-month period under the April 2024 PFAS NPDWR, with quarterly compliance monitoring triggered above the 2.0 ppt threshold.
Public disclosure	No mandatory Consumer Confidence Report. Testing records are kept internally and reviewed during FDA inspections under 21 CFR Part 129, and there is no mandatory public violation notice.	An annual CCR is required by July 1 each year, and twice annually for systems serving 10,000 or more people starting with 2026 data under the 2024 Revised CCR Rule (40 CFR §141.152). Tier 1 violation notices must go out within 24 hours under the EPA Public Notification Rule.
Treatment mandates	No specific treatment technology is required. Producers must show compliance through documented monitoring and testing under 21 CFR Part 129. Firms using a public water system as source water may substitute that system’s compliance certificates for certain chemical testing.	Surface water systems must achieve at least 3-log (99.9%) removal of Giardia, 4-log (99.99%) of viruses, and 2-log removal of Cryptosporidium under the Long Term 2 Enhanced Surface Water Treatment Rule. Disinfection byproduct limits are governed by the Stage 1 and Stage 2 DBP Rules.

One more asymmetry affects how results are generated. Tap-water utilities must use state-certified laboratories for compliance testing. Bottled water producers are not required to do so and may self-test under current FDA rules.

Where Both Frameworks Fall Short on Plastic Content

The comparison above covers the areas both frameworks actually regulate. The regulatory gap noted in the key takeaways is comprehensive: no federal Maximum Contaminant Level for plastic particles, no required testing protocol, and no disclosure obligation tied to their presence. This gap applies equally to bottled and tap water.

Independent research has found plastic particles in both tap and bottled water. A 2018 peer-reviewed study by Kosuth, Mason, and Wattenberg, published in PLOS ONE, found anthropogenic (human-made) particles in 81% of 159 tap water samples sourced across five continents. A separate 2018 study led by Sherri Mason at the State University of New York at Fredonia, published in Frontiers in Chemistry, found plastic contamination in 93% of 259 bottled water samples across eleven brands, at roughly twice the particle concentration found in tap water, with polypropylene, the material used in many bottle caps, as the most commonly identified polymer. Current federal regulation does not address either finding.

Brands that already have laboratory data on plastic content and want to show progress toward plastic-free standards do not have a federal pathway for turning that data into a claim.

The Wellness Quality Institute Plastic-Free Pathway Verification: How Independent Review Works

The Wellness Quality Institute (WQI) is an independent verification body that reviews companies’ existing third-party laboratory data on plastic and microplastic content against a defined standard. This review helps brands substantiate real progress toward plastic-free standards in plain language, instead of making impossible zero-plastic claims. WQI currently serves U.S. companies only.

WQI’s core program is called Plastic-Free Pathway Verification (PFPV), governed by the standard WQI-CS-01. The review process examines a company’s independent laboratory dataset, testing method, product scope, and supporting controls against defined criteria. These criteria align with the California State Water Board’s drinking-water microplastics reference framework as a technical reference point. California serves as a technical anchor, not a geographic boundary, so verification is available to companies nationwide. California has not created, approved, authorized, or endorsed WQI or its standard.

The program starts from a clear technical limit. No laboratory today can confirm the complete absence of plastic across every particle size, polymer type, and production lot. That reality explains why WQI focuses on what the data can honestly show. Every review produces one of two outcomes:

• Standard Met means the dataset satisfies all applicable technical and data-quality requirements, and no reportable target polymer particles are detected within the tested particle-size range and approved reporting limits. This outcome includes a verification decision, a scope-locked license to use the WQI mark, a public registry listing, and approved claim language.
• Standard Not Met means one or more requirements are unsatisfied. This is a private outcome, never described as a failed product, and the company may resubmit with updated information.

Verification is locked to the reviewed product, dataset, tested particle-size range, polymer panel, and production period, which means no company-wide or product-line claim may be extended from a single dataset. This scope limitation keeps claims tightly tied to the evidence actually reviewed. A single assessment fee covers the review, verification decision, and registry listing, with no separate mark-license or registry fee. Independent laboratory testing is arranged and billed separately by a qualified independent laboratory.

For bottled water and functional beverage brands that already hold third-party laboratory data, WQI’s review answers a practical question. The process clarifies what that data actually supports as a defensible market claim.

The approved mark for products meeting the standard is “WQI Plastic-Free Pathway Verified.” The mark does not state that a product is plastic-free. It states that a company’s laboratory data has been independently reviewed against a defined standard and that the data supports genuine progress toward plastic-free standards.

Conclusion: Turning Real Data into Clear Claims

During National Water Quality Month 2026, the regulatory picture for water quality is more active than it has been in years. PFAS compliance timelines are under revision, CCR reporting requirements are expanding, and the FDA is working toward its first bottled-water PFAS standards. The three core differences between FDA bottled-water rules and EPA tap-water rules, testing frequency, public disclosure, and treatment mandates, remain in place and deserve clear attention.

Neither framework addresses plastic content, even as independent studies continue to find plastic particles in both tap and bottled water. Brands that have already commissioned independent laboratory testing now face a different challenge. They must bridge the gap between raw data and a market claim that stays inside what the evidence supports.

The Wellness Quality Institute’s Plastic-Free Pathway Verification offers that bridge. The program provides an independent review process with a defined standard, a public registry, and approved claim language that remains grounded in the actual data.

Frequently Asked Questions

Is bottled water safer than tap water?

Neither framework is simply “safer” than the other, because they regulate different things in different ways. Tap water is subject to more frequent coliform testing, mandatory public disclosure through Consumer Confidence Reports, and specific treatment mandates for surface water systems. Bottled water is regulated as a packaged food, with less frequent required testing and no mandatory public reporting of results. The FDA’s bottled-water standards must be no less stringent than the EPA’s tap-water standards under Section 410 of the FD&C Act, but the two systems differ in how they verify and disclose compliance. Independent research has detected plastic particles in both, and neither framework currently sets any standard for plastic content.

What do FDA labeling requirements for bottled water actually cover?

FDA labeling requirements for bottled water, set out in 21 CFR Parts 129 and 165, cover the type of water, such as spring, purified, or mineral, quality standards for more than 70 chemical substances, and manufacturing practices. Producers must maintain testing and source-approval records and make them available during FDA inspections. The rules do not require any public disclosure of those records. There is no bottled-water equivalent of the Consumer Confidence Report that tap-water utilities must send to customers annually. Some bottlers publish voluntary quality reports, but these reports are not standardized or federally mandated, and their content and format vary widely.

What is the current status of PFAS standards for bottled water in 2026?

The EPA finalized drinking-water limits for six PFAS compounds in April 2024, setting Maximum Contaminant Levels ranging from 4 to 10 parts per trillion. Under Section 410 of the FD&C Act, the FDA must adopt corresponding bottled-water standards that are no less stringent and has stated it is working toward those standards with a deadline in late 2028. If the FDA does not act by that date, the EPA’s limits will automatically apply to bottled water. Separately, in May 2026, the EPA proposed allowing public water systems to request a two-year extension of the PFOA and PFOS compliance deadline, from April 2029 to April 2031, while keeping the MCLs themselves unchanged. Monitoring and reporting requirements remain in force for all systems regardless of whether an exemption is granted.

Why does existing federal regulation not address plastic content in water?

Both the FDA and EPA frameworks were built around contaminants that had well-established measurement methods and health-effects data when the rules were written. These contaminants include bacteria, heavy metals, and disinfection byproducts. Plastic and microplastic content in water represent a newer area of science, and measurement methods are still maturing. There is currently no validated federal analytical method for microplastics in drinking water, no agreed Maximum Contaminant Level, and no consensus on what level, if any, would require regulatory action. As a result, brands with laboratory data on plastic content have no federal framework to reference when substantiating claims, which is the gap that independent verification programs aim to address.

What can a bottled water brand claim if its laboratory data shows low or undetected plastic levels?

A laboratory report showing low or undetected plastic levels provides useful evidence, but it does not automatically translate into a defensible market claim. The finding is limited by the method’s detection floor. “None detected” means none found above the instrument’s lower limit, for the polymers it screened, in the lot it tested. It does not mean none present. Buyers and retailers also tend to discount self-reported results, because the company interpreting its own data has a clear interest in the outcome.

Independent review against a published standard, where a third party with no stake in the result assesses the method, controls, and data, converts a laboratory report into a claim a brand can stand behind. The Wellness Quality Institute’s Plastic-Free Pathway Verification focuses on brands in this position. These are companies that already hold third-party laboratory data and need a defensible, independently reviewed pathway to communicate what that data supports.